Back to results
US 7,252,935 B2Granted
Method of detection of prostate cancer
AssigneeJohn Hopkins University School of Medicine
InventorDavid Sidransky
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and kits useful for detecting neplasia by measuring the methylation level of biomarkers, especially the promoter region of GSTP1 for the detection of prostate adenocarcinoma.
Claims32
A method for indicating an increased likelihood of prostate adenocarcinoma comprising:
- determining a methylation ratio of a tissue sample from a human subject with early stage cancer,
- wherein the methylation ratio is the level of methylation of a bisulfite-treated promoter region of glutathione-S-transferase (GSTP1) relative to a level of bisulfite-treated DNA copy number of a reference gene,
- wherein the early stage cancer is localized prostate cancer,
- wherein the reference gene is MYOD or ACTB,
- wherein a methylation ratio higher than the methylation ratio in tissue from a normal subject is indicative of prostate adenocarcinoma in the subject, and
- wherein a methylation ratio times 1000 of greater than about 3 is indicative of prostate adenocarcinoma in the subject.
3 more elements
A method for indicating an increased likelihood of prostate adenocarcinoma comprising:
- amplifying a promoter region of glutathione-S-transferase (GSTP1) in a biological sample from a subject with early stage cancer by means of oligonucleotide primers in the presence of at least one specific oligonucleotide probe,
- wherein the early stage cancer is localized prostate cancer,
- wherein the promoter region is modified by an agent that modifies unmethylated cytosine to produce a converted nucleic acid,
- wherein the agent is sodium-bisulfite and
- wherein at least one oligonucleotide primer or specific oligonucleotide probe is capable of distinguishing between unmethylated and methylated nucleic acid,
- determining the methylation level of the promoter region by determining the amplification level of the promoter region based on amplification-mediated displacement of the specific oligonucleotide probe,
- wherein a methylation level higher than the methylation level in a normal subject is indicative of prostate adenocarcinoma in the subject.
4 more elements
Dependencies are inferred from the claim text.